Precision radiation zaps untreatable liver tumors in tiny pilot study

NCT ID NCT04903548

Completed Disease control Sponsor: Methodist Health System Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a procedure called selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres) in one patient with liver cancer that could not be removed by surgery. The goal was to see if a flexible dosing approach could improve outcomes like tumor shrinkage, survival, and treatment costs. The study is complete but very small, so its findings are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Y-90 resin microspheres (SIR-Spheres)
What this could lead to: If successful, this approach could offer a more precise way to deliver radiation to liver tumors, potentially improving tumor control and survival while reducing side effects.
What could go wrong: This was a very small, single-center study with only one participant, so results may not apply to others. The procedure carries risks like radiation damage to healthy liver tissue or lungs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.